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Abstract
Osteosarcoma has a complex genetic background, and the response to treatments varies 
among patients. Induction chemotherapy has substantially improved the clinical outcome 
of osteosarcoma. Currently, there is no practical predictive modality in clinical settings, 
and therefore, uniform chemotherapy is applied for all patients. However, since the 
response to induction chemotherapy considerably influences the prognosis, the therapeu-
tic strategy should be optimized for each patient before initiating treatments. Therefore, 
identification and establishment of predictive biomarkers for induction chemotherapy 
have been a long-standing goal in osteosarcoma research. Because of the complex genetic 
traits associated with osteosarcoma, adoption of an omics approach for global gene 
expression is attractive in the search for predictive biomarkers, and omics technologies 
have recently been applied to the development of predictive biomarkers in malignan-
cies, including osteosarcoma. Global studies have been performed at the genome, tran-
scriptome, and proteome levels in osteosarcoma, and various candidate biomarkers have 
been reported using clinical specimens. Further investigation of the clinical utilities of 
these identified predictive biomarkers will be merited through validation and verification 
studies.
Keywords: osteosarcoma, biomarker, chemotherapy, omics, genome, transcriptome, 
proteome
1. Introduction
Osteosarcoma is a rare mesenchymal malignancy, accounting for less than 1% of all adult 
cancers [1]. In contrast, osteosarcoma represents the most frequent type of malignant tumor 
in children and adolescents, and its incidence has increased over time in younger cases [1, 2]. 
Mesenchymal malignancies are classified according to the unique molecular background: 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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those characterized by unique transfusion genes and simple karyotypes, and those without 
unique genetic characters but complex genetic backgrounds [3]. Osteosarcoma is a typical 
example of the latter case and is associated with highly complex karyotypes and frequent 
chromosomal copy number changes [4–11]. The advent of chemotherapy has improved the 
clinical outcome of patients with nonmetastatic osteosarcoma [12–16]. However, despite the 
considerable progress in cancer research, no novel therapeutic strategies for osteosarcomas 
have been established since the 1980s, and the cure rate of osteosarcoma patients has thus 
reached a plateau [15]. Effective molecular targeting drugs that may inhibit specific molecu-
lar aberrations common in certain cancer types are not currently available for osteosarcoma, 
which is likely attributed to the complex molecular backgrounds. Consequently, uniform 
induction chemotherapy is performed for all patients with osteosarcoma.
The identification of predictive biomarkers has been a long-standing goal in osteosarcoma 
research. The response to induction chemotherapy is evaluated by histopathological exami-
nation of tumor necrosis. When a tumor responds to the induction chemotherapy, a better 
prognosis can be expected [17–19]. Studies of the molecular events contributing to the differ-
ent responses to induction chemotherapy have been undertaken using clinical samples. As 
osteosarcoma is not associated with typical genetic alterations, a global approach to investi-
gating the molecular backgrounds may be the most promising strategy. With the advent of 
modern technologies, omics approaches have become increasingly popular in translational 
research and are starting to be applied in the studies of predictive biomarkers in various types 
of cancers, including osteosarcoma.
In this article, we review the researches on potential biomarkers for osteosarcoma with the 
intention to establish predictive biomarkers for induction chemotherapy. Providing an over-
view of the current status of knowledge on these predictive biomarkers will offer a perspec-
tive for further development of osteosarcoma treatments as well as new ideas of what is 
needed to achieve a better clinical outcome for osteosarcoma patients.
2. Omics studies for predictive biomarkers in osteosarcoma
2.1. Genomic studies
Predictive biomarkers based on genomic knowledge have proven to be clinically beneficial 
for various types of malignancies. Schwaederle et al. reported the results of a meta-analysis 
of 570 Phase II studies, including 32,000 patients with various types of malignancies [20]. 
They reported that the use of predictive genomic biomarkers resulted in a higher treatment 
response rate and prolonged progression-free survival as well as overall survival. These 
results should motivate and facilitate the development and use of predictive genomic bio-
markers in osteosarcoma.
Smida et al. reported the DNA copy number alterations and allelic imbalances associated 
with the response to induction chemotherapy using single nucleotide polymorphism (SNP) 
arrays [21]. They investigated the biopsy samples from 44 patients with osteosarcoma who 
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have a record of the subsequent response to chemotherapy. They reported that patients with 
a significantly higher frequency of loss of heterozygosity (LOH) often had a poor response to 
chemotherapy compared to patients with a lower LOH frequency. They also showed that spe-
cific chromosomal regions in chromosomes 10 and 11 were associated with the poor response 
to chemotherapy. Further investigations of these molecules will likely lead to the establish-
ment of novel predictive modalities in osteosarcomas.
Hagleitner et al. investigated 384 SNPs among 54 selected genes in 177 osteosarcoma patients, 
with the aim of identifying genetic variants associated with survival. The 54 genes included 
representative candidate genes involved in the cisplatin and doxorubicin pathway, according 
to the literature and Pharmacogenomics Knowledge Base (https://www.pharmgkb.org/). In 
addition to SNPs associated with progression-free survival, they found 14 SNPs that were sig-
nificantly associated with the poor response to chemotherapy [22]. The clinical utility of these 
14 SNPs has not yet been evaluated, and thus, further investigation is needed for validation.
2.2. Transcriptomic studies
Technologies for comprehensive analyses of mRNA and microRNA expression became avail-
able more than a decade ago and have since been widely used for biomarker development in 
various malignancies [23–28].
Ochi et al. examined the mRNA expression profiles of biopsied tumor tissues from osteo-
sarcoma patients using a cDNA microarray consisting of 23,040 genes [29]. They compared 
six responders and seven nonresponders to induction chemotherapy and identified 60 genes 
whose expression patterns were associated with favorable or poor response to neoadjuvant che-
motherapy. Man et al. identified a novel molecular signature of chemoresistance by comparing 
the profiles of 7 responders and 13 nonresponders using surgically resected tissues after che-
motherapy [30]. They hypothesized that the surgically resected tumor tissues of nonresponders 
were enriched for resistant cells. The identified tissues consisted of 45 unique genes, and their 
predictive performance was confirmed in 14 biopsied tumor tissues obtained before chemo-
therapy. Moreover, the expression levels measured by cDNA microarray were confirmed for 
seven genes using quantitative reverse transcription-polymerase chain reaction (RT-PCR).
Although these three studies had the common goal of identifying predictive biomarkers and 
used biopsy tumor tissues of osteosarcoma patients, the genes involved in the chemoresis-
tance signatures were quite different. This difference may be attributed to the different age 
distributions, small sample sizes, different chemotherapy regimens, and different methods 
used for expression analysis among the studies. Therefore, to establish the clinical utilities of 
the candidate predictive biomarkers, extensive validation studies as well as functional studies 
of the identified genes will be required.
Kubota et al. examined the microRNA expression profiles of open-biopsied tumor tissues 
from osteosarcoma patients using a microarray [31]. They compared four responders and 
four nonresponders to induction chemotherapy and identified six microRNAs whose expres-
sion patterns were associated with favorable or poor response to neoadjuvant chemotherapy. 
They confirmed the significant association of miR-125b and miR-100 with poor response to 
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chemotherapy by RT-PCR. The association between poor prognosis and the abundance of 
miR-125b and miR-100 was confirmed in 20 additional osteosarcoma patients. Overexpression 
of these microRNAs in three osteosarcoma cell lines resulted in the enhanced cell prolifera-
tion, invasiveness, and resistance to chemotherapeutic drugs. As the area under the receiver 
operating curve for these microRNAs were approximately 0.9 (p < 0.01), their clinical applica-
tion is worth challenging. Kubota et al. reported mRNAs whose expression was commonly 
affected by the transfection of miR-125b and miR-100 in osteosarcomas [31]. Those included 
sirtuin (silent mating type information regulation 2 homolog 5, SIRT5), which was previously 
associated with the resistance against therapeutic reagents in nonsmall cell lung cancer [32]. 
Thus, the expression profiles of miRNAs may be linked to those of mRNAs and provide a 
clue to understand the multilayer omics data in osteosarcomas.
2.3. Proteomics studies
Proteomics is another promising approach to biomarker discovery because the proteome is 
the functional translation of the genome, directly regulating the phenotypes of tumors. The 
modalities of proteomics have been considerably developed and applied to several cancer 
biomarker studies. Proteomics provides unique data that cannot be obtained with other tech-
nologies. This level of analysis is important, given the frequent reports of the discordance 
between protein and mRNA expression in global expression studies. In particular, proteomics 
is the only omics modality that can identify the protein status and characteristics such as post-
translational modifications, intra- and extracellular localization, complex formation, activity, 
and degradation. Therefore, adoption of a proteomics approach shows good promise for bio-
marker development in osteosarcoma.
Arai et al. reported the proteins corresponding to the response to chemotherapy reagents in 11 
osteosarcoma cell lines using two-dimensional differential gel electrophoresis (2D-DIGE) [33]. 
They found a differential response to the drugs between monolayer and spheroid cultured 
cells. Among the 4762 protein species observed, they reported the upregulation of cathepsin 
D in spheroid cells that showed resistance to a chemotherapy reagent. Cathepsin D has been 
implicated in chemoresistance, and its clinical utilities were suggested in various malignan-
cies [33]. Saini et al. also compared monolayer and spheroid culture cells using proteomic, 
transcriptomic, and immunophenotyping approaches and identified CBX3 and ABCA5 as 
possible biomarkers for tumor stem cells that showed heterogeneous response to anti-cancer 
drugs [34]. Moreover, they reported that spheres and monolayers showed different responses 
to the approved cancer drugs. The applications of spheroidal cells may offer a great opportu-
nity to evaluate the drug effects in preclinical studies, and adoption of an omics approach will 
be a powerful tool to further develop the biomarkers to predict the response to treatments.
Li et al. reported plasma proteins that may have good predictive performance for osteosar-
coma patients [35]. They investigated the proteome of plasma collected from 54 osteosarcoma 
patients comparing before (n = 27) and after (n = 27) induction chemotherapy. They developed 
two classifiers for responsiveness and revealed that both showed 85% accuracy for prediction 
of response. They also examined the biological backgrounds of serum amyloid protein A and 
transthyretin, which were included in the classifiers. An extensive list of plasma proteins in 
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osteosarcoma patients was established using a proteomics approach [36], which should serve 
as a useful dataset for the plasma proteomics of osteosarcoma.
To characterize the proteome backgrounds associated with resistance to induction chemother-
apy, Kikuta et al. examined the differential protein expression between patients who showed a 
favorable response to induction chemotherapy and those who did not [37]. Among the several 
thousand protein species observed by 2D-DIGE, they focused on peroxiredoxin 2 (PRDX2), an 
enzyme that catalyzes the free radicals produced by catalase and protects cells from oxidative 
stress. The patients with primary tumor tissues showing high PRDX2 expression ultimately 
developed resistance to induction chemotherapy, and vice versa. The results were validated in 
additional cases of osteosarcoma using the specific antibody for PRDX2. Kikuta et al. examined 
osteosarcoma patients who received combination therapy with isofomide, cisplatin, and doxo-
rubicin, and in a subsequent study, Kubota et al. used 2D-DIGE to examine the protein expres-
sion in the osteosarcoma patients who received different versions of induction chemotherapy: 
methotorexate, cisplatin, or doxorubicin [38]. Both studies concordantly identified the high 
expression of PRDX2 in the nonresponders. The functional significance of the high expression 
of PRDX2 was also investigated in an in vitro experiment; the gene silencing of endogenous 
PRDX increased the sensitivity of cells to chemotherapy reagents. These results were repro-
duced using additional osteosarcoma cases receiving the same induction chemotherapy.
3. Future treatments for osteosarcoma patients with poor chemo-response 
potential
One of the most critical questions in the study of predictive biomarkers is what options to offer 
patients who are predicted to show an unfavorable response to induction chemotherapy. Due to 
the lack of predictive biomarkers for chemotherapy response in osteosarcoma, there has been no 
clinical trial conducted to identify patients with poor response. However, many lines of evidence 
suggest several possible therapeutic strategies for osteosarcoma patients. Meyers et al. reported 
that the addition of muramyl tripeptide to chemotherapy improved the overall survival of osteo-
sarcoma patients [39]. Lewis et al. reported the possible application of interleukin-11 receptor 
alpha as a functional target in osteosarcoma [40]. In addition, there are also several possible 
immunotherapies for osteosarcoma. Cripe et al. reported the possible application of treatment 
with a vaccinia virus, pexastimogene devacirepvec, through viral lysis and induction of granu-
locyte macrophage colony-stimulating factor-driven tumor-specific immunity in osteosarcoma 
[41]. Tsukahara et al. demonstrated the possibility of peptide therapy in osteosarcoma [42]. 
Lussier et al. reported that combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 
antibody might be effective for treating metastatic osteosarcoma [43]. Moreover, therapy using 
a genetically modified T cell line has been under evaluation for osteosarcoma patients [44]. 
Because these therapeutic approaches may have different modes of action compared with the 
conventional chemotherapeutic reagents, combinatory treatment of these novel drugs and con-
ventional chemo-agents will promise new therapeutic strategy against osteosarcoma. Clinical 
trials of the novel treatment strategies are strongly desired to establish predictive biomarkers 
especially for the patients with potential of resistance to conventional chemotherapy.
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4. Perspective of predictive biomarker identification with an omics 
approach
The advent of omics technology has made it feasible to observe tens of thousands of genes and 
proteins simultaneously with relative ease. Technologies for omics studies are continuously been 
developed, with expected improvements in terms of accuracy, comprehensiveness, and cost-
effectiveness, which can be applied to osteosarcoma research. Next-generation sequencing (NGS) 
technologies have made it possible to produce even more detailed omics data. For example, NGS-
based methods can be used to obtain the expression data of individual splice variants of mRNAs, 
which are not possible using conventional DNA microarray systems. Therefore, refined data of 
mRNA expression can be obtained by applying the novel technologies to previously examined 
sample sets. Moreover, proteomics was traditionally used to examine only protein expression lev-
els, which do not necessary correlate with protein activity. The recent advent of high-throughput 
technology allows for the measurement of the actual activities of various specific kinases as well 
as nuclear receptors across hundreds of samples in only a few hours. All these omics technologies 
will be useful for advancing the study of predictive biomarkers in osteosarcoma.
One of the major current limitations of current studies for predictive biomarkers in osteosar-
coma would be the small number and amount of clinical materials available. Considering 
the low prevalence of osteosarcoma, it is going to be very difficult to achieve the sufficient 
sample collection by single institutes and individual efforts alone. Therefore, nation-wide 
and/or international collaboration studies will be required.
The perspective provided herein on searching for predictive biomarkers in osteosarcoma, a 
rare malignancy with complex genetic traits, could be applicable to other major malignancies 
like lung cancers. Indeed, a recent NGS-based analysis revealed that the majority of lung can-
cers can be grouped into various minor subtypes according to the clinically important genetic 
aberrations. We believe that innovations developed in rare malignancies like osteosarcoma 
will not only benefit the patients with those diseases but also make a great impact on the 
researches for majority of malignancies.
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